These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1505150)

  • 1. Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in humans.
    Billah MM; Gilchrest HG; Eckel SP; Granzow CA; Lawton PJ; Radwanski E; Brannan MD; Affrime MB; Christopher JD; Richards W
    Clin Pharmacol Ther; 1992 Aug; 52(2):151-9. PubMed ID: 1505150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sch 37370: a potent, orally active, dual antagonist of platelet-activating factor and histamine.
    Billah MM; Chapman RW; Egan RW; Gilchrest H; Piwinski JJ; Sherwood J; Siegel MI; West RE; Kreutner W
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1090-6. PubMed ID: 2319461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and preliminary pharmacology of Sch 37370, a dual antagonist of PAF and histamine.
    Billah MM; Egan RW; Ganguly AK; Green MJ; Kreutner W; Piwinski JJ; Siegel MI; Villani FJ; Wong JK
    Lipids; 1991 Dec; 26(12):1172-4. PubMed ID: 1819703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine.
    Billah MM; Chapman RW; Watnick AS; Egan RW; Siegel MI; Kreutner W
    Agents Actions Suppl; 1991; 34():313-21. PubMed ID: 1793070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine.
    Kaminski JJ; Carruthers NI; Wong SC; Chan TM; Billah MM; Tozzi S; McPhail AT
    Bioorg Med Chem; 1999 Jul; 7(7):1413-23. PubMed ID: 10465415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of plasma concentrations of SCH 44643 by a GC method and correlation of plasma concentration and anti-PAF activity in cynomolgus monkeys.
    Lin CC; Billah M; Kim HK; Egan R; Anthes J; Gilchrest H; Cayen M
    J Pharm Biomed Anal; 1996 Dec; 15(3):343-7. PubMed ID: 8951694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine.
    Barnett A; Iorio LC; Kreutner W; Tozzi S; Ahn HS; Gulbenkian A
    Agents Actions; 1984 Jun; 14(5-6):590-7. PubMed ID: 6236679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous platelet-activating factor (PAF) receptors and calcium increase in platelets and macrophages.
    Centemeri C; Colli S; Tosarello D; Ciceri P; Nicosia S
    Biochem Pharmacol; 1999 Feb; 57(3):263-71. PubMed ID: 9890553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine.
    Carceller E; Merlos M; Giral M; Balsa D; Almansa C; Bartrolí J; García-Rafanell J; Forn J
    J Med Chem; 1994 Aug; 37(17):2697-703. PubMed ID: 7914928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.
    Piwinski JJ; Wong JK; Green MJ; Ganguly AK; Billah MM; West RE; Kreutner W
    J Med Chem; 1991 Jan; 34(1):457-61. PubMed ID: 1671420
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of H1- and H2-antihistamines on platelet-activating factor and bradykinin-induced inflammatory responses in human skin.
    Sansom JE; Brooks J; Burton JL; Archer CB
    Clin Exp Dermatol; 1996 Jan; 21(1):33-7. PubMed ID: 8689766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual antagonists of platelet activating factor and histamine. 3. Synthesis, biological activity and conformational implications of substituted N-acyl-bis-arylcycloheptapiperazines.
    Piwinski JJ; Wong JK; Green MJ; Kaminski JJ; Colizzo F; Albanese MM; Ganguly AK; Billah MM; Anthes JC; West RE
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3469-74. PubMed ID: 9934454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consumption of plant extract supplement reduces platelet activating factor-induced platelet aggregation and increases platelet activating factor catabolism: a randomised, double-blind and placebo-controlled trial.
    Gavriil L; Detopoulou M; Petsini F; Antonopoulou S; Fragopoulou E
    Br J Nutr; 2019 May; 121(9):982-991. PubMed ID: 30940217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
    McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (Pyridylcyanomethyl)piperazines as orally active PAF antagonists.
    Carceller E; Almansa C; Merlos M; Giral M; Bartrolí J; García-Rafanell J; Forn J
    J Med Chem; 1992 Oct; 35(22):4118-34. PubMed ID: 1433215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of platelet activating factor antagonists on the protamine sulphate stimulated release of histamine from peritoneal mast cells of rats in vitro.
    Lohde C; Bahr T; Labes D; Grupe R
    Arzneimittelforschung; 1992 Jan; 42(1):27-31. PubMed ID: 1375025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terfenadine effect on the bronchoconstriction, dermal response, and leukopenia induced by platelet-activating factor.
    Hopp RJ; Townley RG; Agrawal DK; Bewtra AK
    Chest; 1991 Oct; 100(4):994-8. PubMed ID: 1914619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction studies in mice of SCH 29851, a potential non-sedating antihistamine, with commonly used therapeutic agents.
    Iorio LC; Cohen-Winston M; Barnett A
    Agents Actions; 1986 Aug; 18(5-6):485-93. PubMed ID: 2945410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rupatadine, a dual antagonist of histamine and platelet-activating factor (PAF), attenuates experimentally induced diabetic nephropathy in rats.
    Hafez HM; Abdel-Hakeem EA; Hassanein H
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Aug; 393(8):1487-1500. PubMed ID: 32200462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.